Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Scientific reports, 12, Article 6243, S. 6243-1-6243-5
- Ereignis
-
Veröffentlichung
- (wo)
-
Bochum
- (wer)
-
Ruhr-Universität Bochum
- (wann)
-
2022
- Urheber
-
Bertram, Sebastian Johannes
Blazquez-Navarro, Arturo
Seidel, Maximilian
Hölzer, Bodo
Seibert, Felix Sebastian
Doevelaar, Adrian
Rohn, Benjamin Johannes
Zgoura, Panagiota
Witte‑Lack, Alexandra
Skrzypczyk, Sarah
Scholten, David
Kisters, Klaus
Babel, Nina
Westhoff, Timm
- URN
-
urn:nbn:de:hbz:294-103239
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bertram, Sebastian Johannes
- Blazquez-Navarro, Arturo
- Seidel, Maximilian
- Hölzer, Bodo
- Seibert, Felix Sebastian
- Doevelaar, Adrian
- Rohn, Benjamin Johannes
- Zgoura, Panagiota
- Witte‑Lack, Alexandra
- Skrzypczyk, Sarah
- Scholten, David
- Kisters, Klaus
- Babel, Nina
- Westhoff, Timm
- Ruhr-Universität Bochum
Entstanden
- 2022
Ähnliche Objekte (12)
Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages
BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children
Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2
Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages
BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children
Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2
Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages
BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children
Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2
Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination